$CBIS IRVINE, CA--(Marketwired - Nov 16, 2016) - Cannabis Science, Inc. ( OTC PINK : CBIS ), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce that plans to initiate a long awaited medication study for Pulmonary Patients suffering from varying failing lung functions stemming from Cancers to Bronchitis and all in between respiratory ailments. "We expect it will begin as soon as the First Lab and Extraction site is completed and we think this will take place in this month of November," stated CEO and Co-founder Raymond C. Dabney.

http://finance.yahoo.com/news/cannabis-scienc...RzZWMDc2M-

$GRCU $GRNH $CGRW $CANN $CBIS $GRWC $TRTC $MJNA